ACER - Acer Therapeutics rises on starting trial of ACER-801 in men with adenocarcinoma of the prostate

• Acer Therapeutics ( NASDAQ: ACER ) is trading ~5% higher after the company began two Phase 2 investigator-sponsored trials evaluating ACER-801 (osanetant) in men with adenocarcinoma of the prostate.
• The two-trials are - The POSH-MAP, which is Pilot of Osanetant for Severity of Hot Flashes in Men with Adenocarcinoma of the Prostate and PORT-MAP, which is Pilot of Osanetant to Reduce Testosterone in Men with Adenocarcinoma of the Prostate.
• The POSH-MAP trial will evaluate the ability of ACER-801 to reduce hot flash frequency and severity and improve quality of life measures in men with prostate cancer following 28 days of therapy.
• The second trial, PORT-MAP, will evaluate the ability of ACER-801 to suppress testosterone production in men with prostate cancer within 28 days prior to a planned prostatectomy.

For further details see: